Spectrum of centrosome autoantibodies in childhood varicella and post-varicella acute cerebellar ataxia

Marvin J Fritzler*1, Meifeng Zhang2, Laura M Stinton1 and Jerome B Rattner2

Address: 1Department of Medicine, Faculty of Medicine University of Calgary, 3330 Hospital Dr. NW, Calgary, AB T2N 4N1, Canada and 2Department of Cell Biology & Anatomy, Faculty of Medicine University of Calgary, 3330 Hospital Dr. NW, Calgary, AB T2N 4N1, Canada

Email: Marvin J Fritzler* - fritzler@ucalgary.ca; Meifeng Zhang - mzhan@ucalgary.ca; Laura M Stinton - lmstinto@ucalgary.ca; Jerome B Rattner - rattner@ucalgary.ca

* Corresponding author

Abstract

Background: Sera from children with post-varicella infections have autoantibodies that react with centrosomes in brain and tissue culture cells. We investigated the sera of children with infections and post-varicella ataxia and related conditions for reactivity to five recombinant centrosome proteins: γγ-enolase, pericentrin, ninein, PCM-1, and Mob1.

Methods: Sera from 12 patients with acute post-varicella ataxia, 1 with post-Epstein Barr virus (EBV) ataxia, 5 with uncomplicated varicella infections, and other conditions were tested for reactivity to cryopreserved cerebellum tissue and recombinant centrosome proteins. The distribution of pericentrin in the cerebellum was studied by indirect immunofluorescence (IIF) using rabbit antibodies to the recombinant protein. Antibodies to phospholipids (APL) were detected by ELISA.

Results: Eleven of 12 children with post-varicella ataxia, 4/5 children with uncomplicated varicella infections, 1/1 with post-EBV ataxia, 2/2 with ADEM, 1/2 with neuroblastoma and ataxia, and 2/2 with cerebellitis had antibodies directed against 1 or more recombinant centrosome antigens. Antibodies to pericentrin were seen in 5/12 children with post-varicella ataxia but not in any of the other sera tested. IIF demonstrated that pericentrin is located in axons and centrosomes of cerebellar cells. APL were detected in 75% of the sera from children with post-varicella ataxia and 50% of children with varicella without ataxia and in none of the controls.

Conclusion: This is the first study to show the antigen specificity of anti-centrosome antibodies in children with varicella. Our data suggest that children with post-varicella ataxia have unique autoantibody reactivity to pericentrin.

Background

There are 3 million cases of chicken pox each year in the United States and 90% of this infection occurs in children 1–14 years of age [1]. The sequelae of varicella infection in children includes a number of severe complications such as purpura fulminans and thromboembolism [2,3]. In these conditions, autoantibodies to a variety of phospholipids and protein related to coagulation were reported and the related syndrome was referred to as The Varicella-Autoantibody Syndrome [3]. Encephalitis is another of sequelae of varicella in children that accounts for 20% of hospital admissions due to varicella [4]. A
cerebellar syndrome associated with post-infectious and post-vaccinal states that usually begins abruptly 5 to 6 days following the subsidence of a rash, is manifest primarily as ataxia. This syndrome is common following varicella but also appears in measles, rubella and Epstein Barr virus (EBV) infections [1,5–7]. The course is usually mild and most children recover, but it can progress in some children to more severe disease as manifested by vomiting, dehydration and drowsiness. Although central nervous system complications usually develop within a week after eruption, they may be delayed for up to 21 days.

The pathogenesis of post-varicella cerebellar ataxia is unknown. A number of autoantibodies have been described in other post-viral conditions, including antineuronal antibodies in a case of post-infectious cerebellar ataxia following EBV infection [6], antibodies to Purkinje cells in children with opsoclonus myoclonus associated with neuroblastoma or a prodromal viral illness [5], and antibodies to centrioles in 2 children with ataxia and other central nervous system manifestations following Mycoplasma pneumoniae infection [8]. In a recent study of children with post-varicella ataxia, we found antibodies to cerebral and cerebellar tissue [9].

A family of proteins located at the centrosome that react with human autoantibodies include pericentrin, ninein, enolase, PCM 1 and a newer autoantigen, Mob1 [10,11]. These components are part of the pericentriolar material (PCM) that surrounds the centrioles and mediates functions such as microtubule organization and recruitment of proteins to the centrosome. Pericentrin in particular has been shown to be an important structural protein within the PCM [12] and exist as particles in the cytoskeleton. These particles transit to the centrosome via the motor protein dynein [12].

Antibodies directed against centrosome proteins have been described in a number of conditions including arthritis, Raynaud's phenomenon and systemic sclerosis [11,13–18]. In addition, naturally occurring antibodies to centrosomes have been described in laboratory rabbits [19]. The specific antigenic target of many of these autoantibodies remains undefined but with the identification of centrosome components and the availability of the cDNAs and respective recombinant proteins, systematic studies of autoantibody specificity can now be determined with more precision.

Most children with post-infectious ataxia have a mild course but some are more severely affected. If the mechanisms that lead to the development of post-infectious cerebellar ataxia are more completely understood, then a rational approach to treatment could be considered. We investigated the possibility that autoantibodies to specific centrosome proteins are associated with a subset of children with post-varicella acute cerebellar ataxia.

**Methods**

**Patients & Sera**

Children with chicken pox and subsequent cerebellar ataxia were included in this study [8,9,9]. Blood samples were obtained at the first visit and, in all but 4 patients, at a convalescent stage 2 weeks later. We also obtained acute blood samples from 5 siblings of those with post-varicella ataxia with chicken-pox but without ataxia, from 20 normal controls, 20 children with juvenile chronic arthritis, 1 child with post-EBV ataxia, 2 with acute disseminated encephalomyelitis (ADEM), and 1 with neuroblastoma and ataxia, and 1 with cerebellitis. Varicella serology to confirm the clinical diagnosis included an ELISA for IgG antibodies at onset and complement fixation titer at onset and at 2 weeks. Other control sera were from ongoing serological studies in the advanced Diagnostics Laboratory at the University of Calgary. All sera were stored at -20°C.

**Indirect immunofluorescence (IIF)**

Conventional IF was performed on commercially available HEp-2 cells (Immuno Concepts Inc., Sacramento, CA) and formalin-fixed HeLa cells using a fluorescein-conjugated goat anti-human IgG (light and heavy chain) as previously described [20]. Reactivity of patients' sera was also tested on cryopreserved sections of monkey cerebellum (Medica, Carlsbad, CA) by IIF. Rabbit antibodies to pericentrin (a gift from Dr. D.A. Compton, Dartmouth Medical School, Hanover, NH) and human antibodies to the Yo antigen [21] were used in co-localization experiments. In some experiments, DNA was stained with DAPI to allow for co-localization with centrosome staining. Slides were viewed on a Leitz or a Zeiss Universal microscope fitted with a TEC470 CCD video camera system (Optronics Engineering, Goleta, CA) and images were processed with a Sony Color Video Printer and recorded on Sony Type 1010 photography paper.

**Immunoblotting recombinant centrosome proteins**

Recombinant proteins were prepared from full-length cDNAs representing five different centrosome autoantigens using previously published protocols [11,22,23]. Briefly, cDNA inserts were amplified using standard polymerase chain reaction protocols, and subcloned in the Eco RI site of the expression vector pGEX-5X (Pharmacia Biotechnology, Uppsala, Sweden). Expression of recombinant protein fused to a 28 kDa glutathione S transferase (GST) leader sequence was induced with 0.1 mM IPTG. Bacteria were lysed by sonication, and insoluble material was removed by centrifugation. GST fusion proteins were purified directly from the bacterial lysates using the affinity matrix glutathione Sepharose 4B. After
binding and washing, the fusion proteins were eluted under mild non-denaturing conditions using 10 mM reduced glutathione in 50 mM Tris HCl (pH 8.0).

Bacterial lysates that expressed the recombinant proteins were resuspended in sodium dodecyl sulfate sample buffer and denatured by boiling for 5 minutes as previously described [23]. The proteins were separated on a 10% SIDS-polyacrylamide gel, transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA), and incubated with a 1:1000 dilution of the appropriate serum. The recombinant proteins were produced from the SM-3 fragment for human ninein, a clone representing base pairs 45–1778 of pericentrin, a cDNA representing PCM-1 and designated 17A1 [24], two partial cDNAs (SM-1, SM-16) for Cep250, and ninein. Secondary antibodies were polyvalent horse radish peroxidase-conjugated goat antihuman IgG, anti-mouse (IgG) or anti-rabbit IgG, IgA, and IgM (Zymed, San Francisco, CA). Immunoreactive bands were visualized using the ECL Western blotting system (Amersham International, Princeton, NJ) [11].

**Phospholipid ELISA**

An anti-Phospholipid-8Pro-G EIA Kit (Alpco Diagnostics, Windham, NH) was used to test for the presence of antibodies against phospholipids: β2-glycoprotein I, β2-glycoprotein I combined with cardiolipin in the same well (β2-GP1 + CL), CL alone, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, and sphingomyelin. Briefly, the serum samples were diluted to 1:101 and then incubated with the specific antigen in microtiter wells. The unbound antibodies were washed away as per the manufacturer’s instructions. An anti-human immunoglobulin (IgG,A,M) secondary antibody conjugated to horseradish peroxidase was added and incubated for 15 minutes at room temperature. Unbound conjugate was washed off and the addition of TMB-substrate generated an enzymatic colormetric reaction, which was stopped by adding diluted acid. The reactions were read at an absorbance of 450 nm on a Biomek 1000 (Beckman) and cutoffs based on graded control positive and negative control sera provided with the kit.

**Results and discussion**

Eleven of 12 sera from children with post-varicella ataxia had IgG antibodies that reacted with the centrosome of formalin-fixed HeLa cells in an IIF assay (Figure 1). We observed that commercially prepared substrates, such as HEp-2 cells, were not sensitive for the detection of centrosome autoantibodies but that the formalin-fixed HeLa cells are a more reliable and sensitive substrate. When the sera were tested for IgG antibodies by immunoblotting (Figure 2), 10/12 reacted with at least one of the five centrosome proteins: ninein, PCM 1, γγ-enolase, Mob-1, or pericentrin (Table 1). Thus, one serum had autoantibodies to a centrosome antigen that was not included in the proteins listed above. Specifically, 5/12 (42%) reacted with pericentrin (Figure 2), 3/12 (25%) with ninein, 6/12 (50%) with PCM 1, 3/12 (25%) with Mob-1, and 3/11 (27%) with γγ-enolase. By comparison, 3/5 siblings with varicella infections but no ataxia, 1/1 with post-EBV ataxia, 2/2 with ADEM, 1/2 with neuroblastoma and...
ataxia, and 2/2 with cerebellitis had antibodies directed against at least one of the centrosome proteins. None of the 12 sera from other disease groups, including 20 children with juvenile chronic arthritis, or 20 normal controls reacted with pericentrin, although they did react with other recombinant centrosome proteins. When convalescent sera were tested, the frequency of anti-centrosome antibodies as detected by IIF and anti-pericentrin as detected by immunoblotting decreased to 4/12 (33%) of children with post-varicella ataxia, and none of the other children sustained detectable reactivity at two weeks follow-up. The number of sera from children with ataxia that was not associated with varicella is admittedly small and validation of our data would require multi-center studies or access to large neurological or infectious diseases serum banks.

The demographics, clinical profile and outcome of our patients with post-varicella ataxia has been reported elsewhere [9]. We are aware of only one report of virus or viral antigen identification in varicella-associated cerebellar ataxia [25]. A number of autoantibodies have been reported in other post-infectious cerebellar syndromes. Ito and his colleagues reported IgG and IgM anti-neuronal antibodies that reacted with both nuclear and cytoplasmic elements of Purkinje cells in acute cerebellar ataxia following infection [6]. In this study, the IgM reactivity gradually decreased and the ataxia gradually improved. Sera from 9 children with opsoclonus-myoclonus syndrome (3 associated with neuroblastoma and six with a prodromal illness) had IgM and IgG binding to the cytoplasm of cerebellar Purkinje cells and to some axons in white matter. Western blot analysis showed a distinctive pattern of binding to several neural proteins, including a 210 kDa antigen identified as the high molecular weight subunit of neurofilament [7]. Last, two children with central nervous system manifestations (including ataxia) following *Mycoplasma pneumoniae* infection were reported to develop anti-centriole antibodies [8].

### Table 1: Reactivity of sera from ataxia patients with centrosome proteins

| Diagnosis (n)          | Pericentrin n (%) | Ninein n (%) | PCM 1/2 n (%) | Mob1 n (%) | γγ Enolase n (%) |
|------------------------|-------------------|--------------|---------------|------------|-----------------|
| Post-Varicella Ataxia (12) | 5 (42)           | 3 (25)       | 6 (50)        | 3 (25)     | 3 (25)          |
| Varicella              | 0 (0)             | 2 (40)       | 0 (0)         | 1 (20)     | 2 (0)           |
| No Ataxia (5)          | 0 (0)             | 0 (0)        | 1 (100)       | 0 (0)      | 1 (100)         |
| Post-EBV Ataxia (1)    | 0 (0)             | 0 (0)        | 1 (50)        | 1 (50)     | 1 (50)          |
| ADEM (2)               | 0 (0)             | 1 (50)       | 0 (0)         | 1 (50)     | 1 (50)          |
| Neuroblastoma Ataxia (2) | 0 (0)            | 0 (0)        | 1 (50)        | 1 (50)     | 1 (50)          |
| Ataxia                 | 0 (0)             | 0 (0)        | 0 (0)         | 0 (0)      | 0 (0)           |
| Telangiectasia (6)     | 0 (0)             | 0 (0)        | 1 (50)        | 1 (50)     | 1 (50)          |
| Cerebellitis (2)       | 0 (0)             | 0 (0)        | 0 (0)         | 0 (0)      | 0 (0)           |
| JCA (20)               | 0 (0)             | 0 (0)        | 0 (0)         | 0 (0)      | 0 (0)           |

Abbreviations: ADEM, acute disseminated encephalomyelitis; EBV, Epstein Barr virus; JCA, juvenile chronic arthritis.

**Figure 2**

**Immunoblot of purified recombinant pericentrin**

Immunoblot of recombinant GST-pericentrin with sera from children with post-varicella ataxia (lanes c-i), an adult with idiopathic ataxia (lane k), and sera from a patient with scleroderma and anti-centrosome antibodies (lanes l). Controls included rabbit antibodies directed to recombinant pericentrin (lane a), murine antibodies to GST (lane b), and the index human anti-centrosome serum (lane m).
Autoantibodies to centrosomes have also been associated with systemic sclerosis and other conditions [10,11,26–28]. These observations suggest that autoantibodies to centrosomes as detected by IIF are not disease specific. Studies of specific antibodies directed against pericentrin showed that they are found in 27% of systemic sclerosis sera [17]. Although ataxia or central nervous system involvement is unusual in systemic sclerosis, these patients, as well as patients with an autoimmune paraneoplastic syndrome are known to have autonomic nervous system dysfunction that is associated with antibodies directed against antigens in the myenteric complex [29–31].

Since unique reactivity with pericentrin was noted, we proceeded to determine the distribution of pericentrin in cerebellum tissue by IIF. We observed that pericentrin is expressed in cerebellum as evidenced by intense staining of centrosomes and less intense staining of neuronal axons (Figures 3,4). Cells stained by human sera and rabbit antibodies to pericentrin were found throughout the cerebellum including those in the nuclear and granular layers. This observation is consistent with evidence that, in addition to it being a component of centrosomes, pericentrin exists as particles in the cytoplasm [12]. We observed that some cells, particularly certain Purkinje cells, contain numerous particles and more than one centrosome (Figure 3) and strong reactivity was also found in adjacent cells that were consistent with the location and appearance of Bergman glial cells (Figure 4). These observations are consistent with earlier observations that Purkinje cells are polyploid [32,33]. The observation that children with ataxia produce antibodies to centrosome proteins, including pericentrin, and that Purkinje cells are polyploid raises the question of the vulnerability of these cells to autoimmune attack. Although we have no direct evidence to substantiate this hypothesis, in paraneoplastic cerebellar degeneration where ataxia is a dominant clinical feature, anti-Purkinje cell antibodies (APCA or anti-Yo) are believed to be responsible for the Purkinje cell loss that accompanies the disease [34,35]. This is supported by observations that removal of the autoantibodies from the circulation of a paraneoplastic cerebellar degeneration patient provided improvement of cerebellar signs [36].

Of potential relevance to varicella-related ataxia, it was observed that newly assembled viruses disrupt microtubule organization, as well as centrosome duplication and function [37,38]. This provides insight into mechanisms by which varicella infection might lead to altered proteins and neural function, and the subsequent production of autoantibodies. Obviously, additional studies to delineate differential expression of pericentrin and its interaction with viral components in various cells and tissues are required to substantiate this idea. Of interest, recent evidence suggests that the centrosome may be an important locus for MHC class I antigen processing and that targeting antigens to the centrosome enhances the immune response [39].

A recent study [3] reported the presence of anti-phospholipid (APL) antibodies in children with acute varicella
infections. In this study we found 75% of the children with post-varicella ataxia, 50% of children with varicella but no ataxia, and none of the children with post-EBV ataxia or cerebellitis had elevated APL as detected by ELISA. All positive sera reacted with β2-GP1 + CL, three reacted with CL alone, and individual sera reacted with phosphatidyl inositol (post-varicella ataxia), phosphatidyl serine (varicella without ataxia) and sphingomyelin (varicella without ataxia). These results confirmed that children with varicella infections have a high frequency of antibodies to phospholipids. In the previous study these antibodies were found to be transiently associated with infection and were not predictive of thrombotic complications [3]. In the clinical setting of assessing the risk of thrombosis, a functional clotting assay may have more clinical relevance. In our study the most common APL was bound β2-GP1 + CL. However, these antibodies or other the PL antibodies showed no correlation with ataxia. The specificity of APL for varicella infections was indicated by the observation that patients with cerebellitis and post-EBV ataxia did not have APL.

Conclusions
This is the first report to document that children with post-varicella ataxia develop autoantibodies to a variety of centrosome components. The reactivity of sera from children with post-infectious varicella ataxia appears to be unique in that they react with pericentrin. The origin of centrosome autoantibodies as a sequelae of varicella infection and the potential pathogenic role of antibodies to pericentrin await further study.

List of abbreviations
ADEM, acute disseminated encephalomyelitis; APCA, anti-Purkinje cell antibodies; APL, anti-phospholipid antibodies; CL, cardiolipin; EBV, Epstein Barr Virus; GST, glutathione S transferase; IIF, indirect immunofluorescence; JCA, juvenile chronic arthritis; PL, phospholipid; PCM, pericentriolar material.

Competing interests
None

Authors’ contributions
MJF coordinated the clinical and research studies, provided two of the figures and was the primary author of the manuscript; CA collected the sera, provided the clinical information and edited the manuscript; MZ, conducted all the recombinant protein studies and centrosome immunoaassays; LMS, performed all the phospholipid antibody studies and their interpretation; JBR, coordinated the production of centrosome antigens and the immunoblotting studies, provided two of the figures and was an author of the of the manuscript.

Acknowledgements
The authors acknowledge that Dr. Coleen Adams collected the sera and provided clinical information. This research was supported by the Canadian Institutes of Health Research (Grant # MOP 38034) and a grant from the Natural Sciences and Environment Research Council to JBR.

References
1. Straus SE, Ostrove JM, Inchauspé G, Felser JM, Freifeld A, Croen KD and Sawyer PH: Varicella-zoster virus infections: Biology, natural history, treatment and prevention. Ann Intern Med 1988, 108:221-237.
2. Francis RB: Acquired purpura fulminans. Semin Thromb Hemost 1990, 16:310-325.
3. Josephson C, Nuss R, Jacobson L, Hacker MR, Murphy J, Weinberg A and Manco-Johnson MJ: The varicella-autoantibody syndrome. Pediat Res 2001, 50:345-352.
4. Fleischer G, Henry W, McSorley M, Arberer A and Plotkin S: Life-threatening complications of varicella. Am J Dis Child 1981, 135:896-899.
5. Connolly AM, Dodson WE, Preisky AL and Rust RS: Course and outcome of acute cerebellar ataxia. Ann Neurol 1994, 35:673-679.
6. Ito H, Sayama S, Kanazawa N, Saito T, Kowa H, Haga S and Ikeda K: Antineuronal antibodies in acute cerebellar ataxia following Epstein-Barr virus infection. Neurology 1994, 44:1506-1507.
7. Connolly AM, Pestrakon A, Mehta S, Pranzatelli MR and Noetzel MJ: Serum antibodies in childhood opsoclonus-myoclonus syndrome: An analysis of antigenic targets in neural tissues. J Pediatr 1997, 130:878-884.
8. Cimolai N, Mah D and Roland E: Anticentriolar autoantibodies in children with central nervous system manifestations of Mycoplasma Pneumoniae infection. J Neural Neurosurg Psychiatry 1994, 57:638-639.
9. Adams C, Diadori P, Schoenroth L and Fritzler MJ: Autoantibodies in childhood post-varicella acute cerebellar ataxia. Can J Neurol Sci 2000, 27:16-20.
10. Ratnaj JB and Fritzler MJ: Centriole and centrosome autoantibodies. Autoantibodies Edited by: PeterJB and ShoeneildY. The Netherlands, Elsevier Science B.V.; 1996:153-160.
11. Mack GJ, Rees J, Sandblom O, Balczon R, Fritzler MJ and Ratnaj JB: Autoantibodies to a group of centrosomal proteins in human autoimmune sera reactive with the centrosome. Arthritis Rheum 1998, 41:551-558.
12. Doxsey SJ, Stein P, Evans L, Calarco PD and Kirschner M: Pericentrosomal, a highly conserved centrosome protein involved in microtubule organization. Cell 1994, 76:639-650.
13. Osborn TG, Ryerse JS, Bauer NE and Urrhahn JM: Anticentriole antibody in a patient with progressive systemic sclerosis. Arthritis Rheum 1986, 29:142-146.
14. Sato S, Fujimoto M, Ihn H and Takehara K: Antibodies to centrosome and centriole in scleroderma spectrum disorders. Dermatol 1994, 189:23-26.
15. Tuffanelli DL, McKeon F, Kleinsmith D'AM, Burnham TK and Kirschner M: Anticentromere and anticentrosome antibodies in the scleroderma spectrum. Arch Dermatol 1983, 119:560-566.
16. Fritzler MJ and Ratnaj JB: Mitotic spindle apparatus autoantibodies. Autoantibodies Edited by: PeterJB and ShoeneildY. The Netherlands, Elsevier Science B.V.; 1996:501-506.
17. Gavanesco D, Vasquez-abad, McCauley J, Senécal J-L and Doxsey S: Centrosome proteins: a major class of autoantigens in scleroderma. J Clin Immunol 1999, 19:166-171.
18. Balczon R and West K: The identification of mammalian centrosomal antigens using human autoimmune centrosome antisera. Cell Motil Cytoskeleton 1991, 20:121-135.
19. Turksen K, Aubin JE and Kalinova VI: Identification of an centriole-associated protein by antibodies present in normal rabbit sera. Nature 1982, 298:763-765.
20. Fritzler MJ: Autoantibody testing: Procedures and significance in systemic rheumatic diseases. Meth Achiev Exp Pathol 1986, 12:224-260.
21. Fritzler MJ, Kerfoot SM, Feasby TE, Zochodne DW, Westendorf JM, Dalmau JO and Chan EKL: Autoantibodies from patients with idiopathic ataxia bind to M-phase phosphoprotein I (MPP-1). J Invest Med 2000, 48:28-39.
22. Gao L, Perrelet A and Rothman JE: Vesicles on strings: Morphological evidence for processive transport within the Golgi stack. Proc Natl Acad Sci USA 1998, 95:2279-2283.
23. Ratnaj JB, Rees J, Arnett FC, Revelle JD, Goldstein R and Fritzler MJ: The centromere kinesin-like protein, CENP-E an autoantigen in systemic sclerosis. Arthritis Rheum 1996, 39:1355-1361.
24. Balczon R, Bao LM and Zimmer WE: PCM-1, a 228 kDa centrosome autoantigen showing distinct cell cycle distribution. J Cell Biol 2000, 142:783-793.
25. Peters ACB, Verstrepp J, Lindeman J and Bots GTAM: Varicella and acute cerebellar ataxia. Arch Neurol 1978, 35:769-771.
26. Rechlin M and Mattoli M: Description of serological reaction characteristic of polymyositis. Clin Immunol Immunopathol 1976, 5:12-20.
27. Moroi Y, Muratu I and Takeuchi A: Human anticihelate autoantibody in patients with scleroderma and Raynolds's phenomenon. Clin Immunol Immunopathol 1983, 29:381-390.
28. Bao L, Zimmer WE and Balczon R: Autoeptope mapping of the centrosome autoantigen PCM-I using sclerodema sera with anticusome autoantibodies. Autoimmun 1995, 22:219-228.
29. Altermann HJ, Williams CL and Lennon VA: Paraneoplastic cerebellar autoantibodies associated with gynecological cancer bind to myenteric plexus neurons. Ann Neurol 1991, 29:687-688.
30. Hayhoe S, Eaker EY, Sallustio JE, Peebles C, Tan EM and Williams R.C.Jr: Antimyenteric neuronal antibodies in scleroderma. J Clin Invest 1994, 94:761-770.
31. Eaker EY, Kuldau JG, Verne GN, Ross SO and Sallustio JE: Myenteric neuronal antibodies in scleroderma: Passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med 1999, 133:551-556.
32. Lapham LW: Tetraploid DNA content of Purkinje neurons of human cerebellar cortex. Science 1968, 159:310-312.
33. Swartz FJ and Bhannagar KP: Are CNS neurons polyplid? A critical analysis based upon cytophotometric study of the DNA content of cerebellar and olfactory bulbar neurons of the rat. Brain Res 1981, 208:267.
34. Dalmau J, Gultekin HS and Posner JB: Paraneoplastic neurologic syndromes: Pathogenesis and physiopathology. Brain Pathol 1999, 9:275-284.
35. Lucchini CF, Kimmel DW and Lennon VA: Paraneoplastic and onologic profiles of patients seropositive for type I antineuronal nuclear autoantibodies. Neurology 1998, 50:652-657.
36. Nitschke M, Hochberg F and Drogojo E: Improvement of paraneoplastic opsonoscleritis-myelosclerosis after protein A column therapy. N Engl J Med 1995, 332:192-192.
37. Neugebauer KM, Merritt JT, Wiener MH, Lahita RG and Roth MB: SR proteins are autoantigens in patients with systemic lupus erythematosus - Importance of phosphophetopites. Arthritis Rheum 2000, 43:1768-1778.
38. Ploubidou A, Moreau V, Ashman K, Reckmann I, Gonzalez C and Wy M: Vaccina virus infection disrupts microtubule organization and centrosome function. EMBO 2000, 19:3932-3944.
39. Hung CF, Cheng WF, He L, Ling M, Jiang J, Lin CT and Wu TC: Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 2003, 63:2393-2398.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2431/3/11/prepub